Table 4.

Kaplan‐Meier estimates of survival among patients with FTD/TPI vs. regorafenib as index therapy

Time period after index date	Proportion of patients that survived
	All patients			Among patients in 2L and 3L of treatment
	FTD/TPI, n = 126	Regorafenib, n = 95	p value	FTD/TPI, n = 47	Regorafenib, n = 33	p value
1 month	98.4%	94.7%	.126	97.9%	97.0%	.808
2 months	92.0%	84.1%	.071	95.7%	78.8%	.021 a
3 months	86.2%	73.4%	.016 a	84.6%	66.7%	.045 a
4 months	79.6%	65.8%	.017 a	75.6%	54.5%	.034 a
5 months	64.2%	60.1%	.275	58.7%	51.5%	.275
6 months	58.9%	55.5%	.313	51.1%	48.5%	.420
Median OS (95% CI), mo	7.5 (6.0–8.8)	7.1 (5.0–8.2)	.312	7.7 (4.4–11.5)	5.1 (2.9–7.9)	.073

^a p value <.05.

Abbreviations: 2L, second line; 3L, third line; CI, confidence interval; FTD/TPI, trifluridine/tipiracil; OS: overall survival.